Brief: Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) At The British Thoracic Society Winter Meeting 2024

Savara

22/11/2024 13:36

Nov 22 (Reuters) - Savara Inc  SVRA.O :
    * SAVARA ANNOUNCES ENCORE PRESENTATION OF RESULTS FROM THE
PHASE 3
IMPALA-2 TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION
(MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR
PROTEINOSIS (APAP) AT THE BRITISH THORACIC SOCIETY WINTER
MEETING 2024

Source text:  ID:nBwbKCGF3a 
Further company coverage:  SVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))